Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments

A method of treating the underlying biochemical symptoms of neurological diseases in a mammal, said method comprising a systemic administration of a composition consisting essentially of (a) at least one required primary agent administered orally to said mammal in a therapeutically effective amount in a dosage range of from about 15 mg/kg/day to about 450 mg/kg/day, said required primary agent being a pharmaceutically acceptable salt, free acid or pharmaceutically acceptable ester of the phenyl, cyclohexadiene, cyclohexene or cyclohexane carboxylic acid chemical structure of the formula

• wherein
• R1 is selected from the group consisting of —NH2;
• ε-aminoalkyl having 1-10 carbons linear or branched and hydroxylated derivatives of this structure;
• —NHC(═NH)NH2;
• —(CH2)nNHC(═NH)NH2 wherein n is 1-10 hydrocarbons linear or branched and hydroxylated derivatives of this structure;
• —C(═NH)NH2;
• —(CH2)n—CH═NH(═NH)NH2 wherein n is 1-10 hydrocarbons linear or branched and hydroxylated derivatives of this structure;
• —NHC(═NH)NHNH2;
• —(CH2)nNHC(═NH)NHNH2 wherein n is 1-10 hydrocarbons linear or branched and hydroxylated derivatives of this structure;
• —(CH2)n—CH═NC(═NH)NHNH2 wherein n is 1-10 hydrocarbons linear or branched and hydroxylated derivatives of this structure;
• —NHNHC(═NH)NH2;
• —(CH2)nNHNHC(═NH)NH2 wherein n is 1-10 hydrocarbons linear or branched and hydroxylated derivatives of this structure;
• and —(CH2)n—CH═N—NHC(═NH)NH2 wherein n is 1-10 hydrocarbons linear or branched and hydroxylated derivatives of this structure;
• R2 is selected from the group consisting of H;
• —NH2;
• —OH;
• —O—CH3;
• —OR′ wherein R′ is alkyl of 2-10 hydrocarbons linear or branched and hydroxylated derivatives of this structure;
• ε-aminoalkyl wherein the alkyl group is 1-10 hydrocarbons linear or branched and hydroxylated derivatives of this structure;
• —SO3H;
• —CH3;
• and —(CH2)nCH3 wherein n is 1-10 hydrocarbons linear or branched and hydroxylated derivatives of this structure;
• and
• R′ and R″ are H, —OH or —CH3;
• and m is 0 or 1;
• (b) optionally in combination with a therapeutically effective amount of one or more additional co-agent selected from the group consisting of non-absorbable polyamine carbonyl trapping substances, antioxidants, vitamins, metabolites at risk of depletion, sulfhydryl substance co-agents and co-agents which may facilitate glutathione activity;
• (c) optionally in combination with one or more co-agent medicament in an amount effective to treat the neurological disease;
• said composition furthermore optionally including (d) a pharmaceutically acceptable carrier suitable for the orally administered component thereof wherein the carrier is selected from the group consisting of carboxymethyl cellulose, microcrystalline cellulose, cellulose, starch, dicalcium phosphate, tricalcium phosphate, stearic acid, magnesium stearate, silica, soy flour, watercress, yeast, alfalfa, parseley, lecithin, rice bran, gum tragacanth, gum guar, gum agar, gum arabic, gum carrageenan, gum ghatti, gum karaya, locust bean gum, gum mastic, gum mesquite and gum xanthan, which may include all of the ingredients of said composition;
• and said composition furthermore optionally including (e) a pharmaceutically acceptable carrier suitable for systemic administration by the intravenous, intramuscular or subcutaneous route of one or more co-agent medicament.